N/A
N=449
Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
Esophagogastroduodenoscopy · Colonoscopy
Bottom Line
View on ClinicalTrials.gov: NCT02264249 ↗Enrolled (actual)
449
Serious AEs
0.0%
Results posted
Sep 2016
Primary outcome: Primary: Residual Gastric Volumes of Different Bowel Preparation Regimens — 19; 16; 18 mL
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Esophagogastroduodenoscopy and colonoscopy split dose prep (Other); Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep (Other); Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- The Cleveland Clinic
- Primary completion
- Nov 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Residual Gastric Volumes of Different Bowel Preparation Regimens |
19; 16; 18 | — |
| SECONDARY pH of Gastric Fluid of Different Bowel Preparation Regimens |
2.1; 2.5; 2.5 | — |
| SECONDARY Procedure Complications (Decrease in Oxygen Saturation) |
1; 6; 11 | — |
Summary
The purpose of this study is to determine residual gastric volume and residual gastric pH in patients undergoing combined EGD and colonoscopy comparing the standard single dose prep with the split dose bowel preparation and same day bowel preparations.
Eligibility Criteria
Inclusion Criteria
- Adult patients (ages 18 and over) scheduled for elective non-emergency outpatient combined Esophagogastroduodenoscopy and colonoscopy procedures at CCF. No additional intervention will be done other than the procedure they were scheduled for.
Exclusion Criteria
- Upper GI or lower GI bleeding at the time of procedure
- Large amounts of vomiting reported before the procedure (with bowel preparation)
- Hospital inpatients
- History of abdominal surgery
- History of gastroparesis or other documented GI transit disorder (ex. Colonic inertia)
- Pregnancy Patients with diabetes mellitus taking Metoclopramide without proven gastroparesis by formal testing will not be excluded.
Data sourced from ClinicalTrials.gov (NCT02264249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.